Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.47 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.60 |
| ▸ | GANAB | Q14697 | 1/20 | 0.60 |
| ▸ | PYGL | P06737 | 2/20 | 0.47 |
| ▸ | GLB1 | P16278 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 2/20 | 0.43 |
| ▸ | AGL | P35573 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9382618 | 1.00 | GBA1 (0.60) | GBA1GANABGAAPYGLGLB1 | |
| Hydrochloric Acid SCHEMBL9497390 | 1.00 | GBA1 (0.60) | GBA1GANABGAAPYGLGLB1 | |
| Hydrochloric Acid SCHEMBL9496174 | 1.00 | GBA1 (0.60) | GBA1GANABGAAPYGLGLB1 | |
| SCHEMBL2265142 | 0.98 | GBA1 (0.62) | GBA1GANABGAAPYGLGLB1 | |
| SCHEMBL19328384 | 0.98 | GBA1 (0.62) | GBA1GANABGAAPYGLGLB1 | |
| SCHEMBL23531404 | 0.98 | GBA1 (0.62) | GBA1GANABGAAPYGLGLB1 | |
| SCHEMBL612200 | 0.98 | GBA1 (0.62) | GBA1GANABGAAPYGLGLB1 | |
| SCHEMBL9495785 | 0.98 | GBA1 (0.62) | GBA1GANABGAAPYGLGLB1 | |
| SCHEMBL7032907 | 0.98 | GBA1 (0.62) | GBA1GANABGAAPYGLGLB1 | |
| SCHEMBL14246910 | 0.98 | GBA1 (0.62) | GBA1GANABGAAPYGLGLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004156-A1 | Small Compounds That Correct Protein Misfolding and Uses Thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2010-01-07 | — | — | US | claimed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2720539-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9757370-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| US-20100104644-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100004156-A1 | Small Compounds That Correct Protein Misfolding and Uses Thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090291919-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090286808-A1 | Opsin Stabilizing Compounds and Methods of Use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| EP-1909812-A2 | SMALL COMPOUNDS THAT CORRECT PROTEIN MISFOLDING AND USES THEREOF | University of Florida Research Foundation, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1766416-A1 | USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES | DIGILAB BioVisioN GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007014327-A2 | SMALL COMPOUNDS THAT CORRECT PROTEIN MISFOLDING AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-1619503-A1 | Use of standards for monitoring alterations of peptide and protein samples | BioVisioN AG (DE) | 2006-01-25 | — | — | EP | disclosed |
| WO-2006005622-A1 | USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES | DIGILAB BIOVISION GMBH (DE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | CRYAB, CRYAA, PDE6C | GAA 2173/4885GLA 1531/4885GBA1 1577/4885 |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | GAA 1869/4885GLA 2358/4885GBA1 1142/4885 |
| US-20090291919-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity | ALDH1A2, EYA3, PDE6C | GAA 1301/4885GLA 126/4885GBA1 1698/4885 |
| US-20100104644-A1 | Compositions and Methods for Treating or Preventing Ophthalmic Disease | ALDH1A2, PDE6C, EYA3 | GAA 369/4885GLA 74/4885GBA1 190/4885 |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | CRYAB, CRYAA, PDE6C | GAA 2189/4885GLA 1598/4885GBA1 1642/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | GAA 1869/4885GLA 2358/4885GBA1 1142/4885 |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, PDE6C | GAA 2480/4885GLA 1625/4885GBA1 1702/4885 |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | GAA 2480/4885GLA 1625/4885GBA1 1702/4885 |
| US-20090286808-A1 | Opsin Stabilizing Compounds and Methods of Use | CRYZ, NR2E3, CRYAB | GAA 1002/4885GLA 552/4885GBA1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.